FDA Inspection 1086716 — Marshallton Capital Group
The FDA completed an inspection of Marshallton Capital Group on March 15, 2019 in Newark, DE. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- March 15, 2019
- Fiscal Year
- 2019
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Newark, DE (United States)